Moderna Breakthrough Accelerates China’s Race for Therapeutic Cancer Vaccines

The catalyst was the Phase III INTerpath-001 trial of intismeran autogene, an individualised mRNA treatment jointly developed by Moderna and Merck. The global study enrolled 1,137 patients whose stage IIB to IV melanoma had been completely removed by surgery but who remained at high risk of recurrence. The combination of intismeran and Merck’s Keytruda achieved statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared with Keytruda alone. It was the first positive Phase III result for an individualised neoantigen treatment and an mRNA-based cancer therapy. Moderna’s share price rose almost 177 per cent on August 19, adding roughly US$45 billion to its market value, while Merck and other biotechnology stocks also advanced sharply. However, the companies have not yet released the full Phase III data, and the trial is continuing to assess overall survival.

Despite being described as a vaccine, intismeran is not intended to prevent cancer in healthy people. It is a therapeutic treatment created after a patient develops a tumour. Scientists sequence the tumour, identify mutations that are absent from healthy cells and use mRNA to instruct the immune system to recognise selected tumour-specific neoantigens. Intismeran can encode as many as 34 targets tailored to an individual patient. Keytruda then removes an immune-system “brake,” potentially allowing the vaccine-generated T-cell response to attack residual cancer cells more effectively. This approach is particularly attractive after surgery, when the number of remaining cancer cells may be low but recurrence risk remains substantial. Its success in melanoma has nevertheless not established that the method will work equally well in less immunogenic cancers such as pancreatic, gastric or some forms of lung cancer.

China’s interest is supported by both medical need and industrial scale. National Cancer Centre estimates indicate that the country recorded approximately 5.15 million new cancer cases and 2.58 million cancer deaths in 2024. Analysts estimate that Chinese companies have already assembled more than 100 cancer-vaccine programmes. Everest Medicines is among the more visible mRNA developers. Its personalised vaccine EVM16 uses an artificial-intelligence system to select neoantigens and an LNP delivery system to carry the mRNA. In a first-in-human study involving nine patients with advanced or recurrent solid tumours, eight developed strong neoantigen-specific T-cell responses, and no dose-limiting toxicity was reported. These findings support further research, but the extremely small sample means they cannot yet establish a survival benefit or commercial value.

Hengrui-linked Ruihongdi has advanced RGL-270, a personalised neoantigen mRNA vaccine designed to reduce recurrence after surgery for malignant solid tumours, into clinical evaluation after receiving Chinese regulatory clearance. CanSino Biologics has also expanded its position by partnering with Deppwise Biologics to develop personalised therapeutic mRNA vaccines for gastrointestinal solid tumours and rare cancers. The agreement combines CanSino’s delivery, formulation and manufacturing capabilities with Deppwise’s artificial-intelligence platform for neoantigen discovery. Meanwhile, CK Life Sciences’ Sequencio Therapeutics has around 20 mainly preclinical cancer-vaccine projects and is exploring several delivery formats, including mRNA, circular RNA, peptides and proteins. Two of its leading candidates are not expected to enter clinical trials until late 2027 or early 2028, highlighting the development gap between most Chinese programmes and Moderna’s late-stage asset.

The financial-market response has moved considerably faster than the science. On August 20, Everest Medicines rose by more than 80 per cent at one point, while CanSino’s Hong Kong-listed shares gained as much as 71 per cent. Mainland stocks linked to mRNA production, lipid nanoparticles, genomic sequencing and contract manufacturing also reached daily trading limits, even though several companies had little direct exposure to therapeutic cancer vaccines. The rally reflects the possibility that a successful new treatment class could generate demand across an entire supply chain, from tumour sequencing and AI-based antigen selection to specialised manufacturing and checkpoint-inhibitor combinations. It also creates a risk that early-stage platforms will be valued as though regulatory success were already assured.

The decisive challenge will be translating individualised science into an affordable, repeatable industrial process. Every personalised vaccine requires tumour sampling, high-quality sequencing, algorithmic target selection, custom manufacturing, quality control and delivery within a clinically useful period. This process must operate across hospitals while meeting pharmaceutical manufacturing standards, and the final therapy may still need to be combined with costly immunotherapies. Chinese developers could gain an advantage from lower research costs, large patient populations and faster investigator-initiated studies, but only well-controlled trials can demonstrate whether early immune responses produce longer survival. The companies most likely to create lasting value will be those that can generate convincing Phase II and Phase III data, manufacture vaccines quickly and secure reimbursement—not simply those whose shares benefit from the current mRNA investment frenzy.